Nested Therapeutics Inc. has obtained FDA clearance of its IND application for NST-628 for the treatment of patients with advanced solid tumors harboring genetic alterations in the RAS-MAPK pathway.
E1A binding protein (EP300) and CREB binding protein (CBP) are two closely related histone acetyltransferases (HATs), the mutations in which are related to several cancers. In the current study, researchers from Daiichi Sankyo Co. Ltd. aimed to develop orally available small molecule EP300/CBP HAT inhibitors with antitumor activity.
Volastra Therapeutics Inc. has entered into partnerships with Microsoft Corp., Function Oncology Inc. and Tailor Bio Ltd. with the goal of expanding the potential use of its KIF18A inhibitors.
Investigators at Incyte Corp. have reported details on the discovery and preclinical characterization of new potent and selective inhibitors of cyclin-dependent kinase 2 (CDK2) as potential anticancer candidates.
Researchers from Merck & Co. Inc. have presented the discovery of inhibitors of the YAP/TAZ-TEAD complex as potential anticancer agents. YAP and its paralogue TAZ act as terminal effectors of the Hippo signaling pathway by regulating the transcriptional activity of the different TEAD isoforms.
An increasingly popular target across varied cancer types is the immune system regulator V-domain Ig suppressor of T-cell activation (VISTA), where a number of developers have taken early stage aim – among them Sensei Biotherapeutics Inc., with SNS-101, which Wainwright analyst Edward White believes could be the first anti-VISTA monoclonal antibody approved as a therapeutic agent. But there’s plenty of work ahead.
Japan’s Ministry of Health, Labor and Welfare approved Astellas Pharma Inc.’s Vyloy (zolbetuximab) to treat a type of advanced gastric cancer on March 26, making it the first anti-claudin 18.2 monoclonal antibody to gain regulatory clearance worldwide.
Auron Therapeutics Inc. has described proteolysis targeting chimeras (PROTACs) comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety covalently linked to a histone acetyltransferase KAT2A and/or KAT2B (PCAF)-targeting moiety through a linker.
Nutshell Biotech (Shanghai) Co. Ltd. has synthesized macrocyclic compounds acting as CDK2/cyclin E1 inhibitors reported to be useful for the treatment of cancer.
Vesper Bio ApS has disclosed sortilin (NT3; Gp95) antagonists reported to be useful for the treatment of cancer, hearing loss, inflammation, neurodegeneration, pain, and psychiatric, cardiovascular and renal disorders, among others.
RSS
